{"id":"NCT03837938","sponsor":"Dompé Farmaceutici S.p.A","briefTitle":"Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough","officialTitle":"Multicenter Open-label Randomized Clinical Trial of the Efficacy and Safety of Levopront® Syrup 30 mg/5 ml in Comparison With Libexin® 100 mg Tablets in Patients With Dry Non-productive Cough Caused by Acute Upper Respiratory Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-09","primaryCompletion":"2018-03-06","completion":"2018-07-31","firstPosted":"2019-02-12","resultsPosted":"2024-04-15","lastUpdate":"2024-04-16"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cough"],"interventions":[{"type":"DRUG","name":"Levopront® syrup 30 mg/5 ml","otherNames":["levodropropizine"]},{"type":"DRUG","name":"Libexin®","otherNames":["prenoxdiazine"]}],"arms":[{"label":"Levopront® syrup 30 mg/5 ml","type":"EXPERIMENTAL"},{"label":"Libexin® 100 mg tablets","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective:\n\nTo assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8.\n\nThe daytime cough symptoms resolution corresponds to 0 or 1 points on the \"Six-point daytime and nighttime cough assessment scale\".\n\nSecondary objectives:\n\nTreatment effect assessment in terms of the following efficacy and safety parameters:\n\n* To assess the efficacy of Levopront® in comparison with Libexin® based on nighttime cough resolution rate by Day 8.\n* Daytime and nighttime cough symptoms resolution according to \"Six-point daytime and nighttime cough assessment scale\" by Day 4.\n* Change in severity and frequency of daytime and nighttime cough according to \"Six-point daytime and nighttime cough assessment scale\" on Day 4 and Day 8 from baseline on Day 1.\n* Cough intensity change according to the visual-analogue scale on Day 4 and Day 8 from baseline on Day 1.\n* Change of FEV1 on Day 8 from baseline values on Day 1.\n* Rate of Adverse events (AE) and Serious Adverse Events (SAE) of the various severity according to subjective complaints, laboratory test results, physical examination, vital signs and spirometry","primaryOutcome":{"measure":"Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population","timeFrame":"At Visit 3, Day 8","effectByArm":[{"arm":"Levopront® Syrup 30 mg/5 ml","deltaMin":67,"sd":null},{"arm":"Libexin® 100 mg Tablets","deltaMin":64,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":92},"commonTop":["Headache","Dry mouth","Alanine aminotransferase increased","Hypoaesthesia oral","Nausea"]}}